Lausmed Kft.
Baja H-6500
3 studies enrolling now · 14 studies all time
What they study most
Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Coronary Heart Disease (CHD), Diabetes Mellitus, Type 2, Dyslipidemia, Heart Failure, Hyperlipidemia, Hypertension, Obesity, Overweight, Severe Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM)
Studies at this site
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure — Recruiting now
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
- Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial — Running, not enrolling
- Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight — Running, not enrolling
- CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) — Running, not enrolling
- A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) — Running, not enrolling
- A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) — Completed
- A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia — Completed
- Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) — Stopped early
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease — Running, not enrolling
- Investigational Study of Delayed Release Metformin — Paused
- Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events — Completed